Most Popular
-
1
1 in 3 Koreans live alone, family types becoming diverse
-
2
Korea, Japan finance chiefs vow to tame rampant FX market volatility
-
3
US 'incredibly concerned' about suspected NK-Iran military ties
-
4
K-pop group's manager dismissed for setting up spycam in theater dressing room
-
5
K-pop singer lost consciousness after being hit by foul ball, cancels show
-
6
Korean Muslim YouTuber's plan to build mosque in Incheon goes viral
-
7
Contentious grain bill put directly to plenary meeting for vote
-
8
Why is Apple Pay struggling to get purchase in Korea?
-
9
Yoon's office denies considering liberal figures for key posts
-
10
Seoul says Fu Bao loan 'not going to happen'
Celltrion picks TEVA as biosimilar distributor in N. America
By 황유미Published : Oct. 6, 2016 - 16:15
[THE INVESTOR] Celltrion Healthcare announced on Oct. 6 that it has chosen TEVA as a distributor for biosimilars Truxima and Herzuma in the US and Canada.
The multinational pharmaceutical company based in Israel will pay US$160 million upfront and will split the profit from commercializing the two biosimilars developed by Celltrion.
Truxima’s reference drug is rheumatoid arthritis and non-Hodgkin’s lymphoma treatment Rituxan, and Herzuma’s is breast cancer treatment Herceptin. Both are blockbuster drugs sold by Roche with a combined 13 trillion won global turnover.
Celltrion Healthcare has been negotiating with multiple candidates after the sales rights of the biosimilars were returned by Pfizer in September following its merger with Hospira.
By Hwang You-mee (glamazon@heraldcorp.com)
The multinational pharmaceutical company based in Israel will pay US$160 million upfront and will split the profit from commercializing the two biosimilars developed by Celltrion.
Truxima’s reference drug is rheumatoid arthritis and non-Hodgkin’s lymphoma treatment Rituxan, and Herzuma’s is breast cancer treatment Herceptin. Both are blockbuster drugs sold by Roche with a combined 13 trillion won global turnover.
Celltrion Healthcare has been negotiating with multiple candidates after the sales rights of the biosimilars were returned by Pfizer in September following its merger with Hospira.
By Hwang You-mee (glamazon@heraldcorp.com)
![[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/18/20240418050645_0.jpg&u=20240418181020)
![[Today’s K-pop] Zico drops snippet of collaboration with Jennie](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/04/18/20240418050702_0.jpg&u=)